Nurix Stock Plunges 37%, Wiping Out $1 Billion, After Sanofi Ends Partnered Drug Program

Sanofi is terminating the oral STAT6 degrader program it shared with Nurix, though other licensed programs remain.

Share
Nurix Stock Plunges 37%, Wiping Out $1 Billion, After Sanofi Ends Partnered Drug Program

Nurix Therapeutics shares fell 36.72% to $16.34 in Wednesday trading, as of 9:41 a.m. ET, erasing about $1 billion in market value, the session after partner Sanofi said it is ending its oral STAT6 degrader program. Nurix, which develops drugs designed to remove disease-causing proteins, disclosed the termination in an 8-K filed Tuesday.

Sanofi pulls the plug on STAT6

The filing says Sanofi has halted SAR448272 and shut the program down, ending its first-in-human study. Nurix loses all future payments tied to that program.

It can still earn milestones and royalties on the other programs licensed to Sanofi.

The stock was on pace for its biggest one-day drop in at least 275 trading sessions, since Oct. 1, 2025. Its market value stood at about $1.8 billion after the drop.

A run that ran into a partner exit

Nurix shares were up about 36% year to date at Tuesday's close, ahead of the S&P 500's gain of about 11%, and had risen 12% over the previous month.

In its third-quarter results, the company said it earned $27 million from collaborations with Gilead, Pfizer and Sanofi. That included a $10 million milestone from Sanofi for dosing the first patient in this same STAT6 trial.

What Nurix still has

The company has three clinical-stage candidates of its own: bexobrutideg and zelebrudomide, which degrade a protein called BTK, and NX-1607, which inhibits a protein called CBL-B. It also earns revenue from collaborations with Gilead, Sanofi and Pfizer.

In its latest results, Nurix said it dosed the first patient in a Phase 3 trial of bexobrutideg in chronic lymphocytic leukemia, a late-stage study run under its collaboration with Roche. It reported $1.1 billion in cash, cash equivalents and marketable securities, with a runway into the second half of 2029.

The Sanofi milestone Nurix booked last quarter was for starting the trial that is now being shut down.

Sources

More on Nurix Therapeutics

All Nurix Therapeutics (NRIX) coverage →